1. Introduction {#sec1-biomolecules-10-00010}
===============

The voltage-gated potassium channel Kv1.5, which mediates the cardiac ultra-rapid delayed-rectifier (*I*~Kur~) current in cells \[[@B1-biomolecules-10-00010]\], is an attractive familial atrial fibrillation (AF) type 7 drug target, because it is selectively expressed in the atria but not in the ventricles of human cells \[[@B2-biomolecules-10-00010]\]. AF is the most common cardiac arrhythmia facing physicians, afflicting 13% of men and 11% of women over 85 years of age. In atrial tissue from AF donors, the inhibition of *I*~Kur~ extends the repolarization phase of the atrial cardiac action potential, thereby providing desirable antiarrhythmic effects without the risk of drug-induced torsade de pointes. It is noteworthy that loss-of-function Kv1.5 mutations are associated with AF, and many companies are currently exploring *I*~Kur~ modulators for the treatment of AF \[[@B3-biomolecules-10-00010]\].

The Kv1.5 protein is encoded by the KCNA5 gene with a length of 602 amino acids in mice (Unitprot Entry: Q61762) and rat (Unitprot Entry: P19024) sequences and 613 amino acids in the human sequence (Unitprot Entry: P22460). According to the Basic Local Alignment Search Tool (BLAST) result, the sequence of Kv1.5 is similar to homology targets Kv1.1, Kv1.2, and Kv1.3 in most regions, whereas differences mainly occur toward the start and end terminals of the sequence (see [Figure 1](#biomolecules-10-00010-f001){ref-type="fig"}C,D). The Kv1.5 channel belongs to the shaker-type voltage-gated K^+^ channel family, and it comprises four pore-forming *α*-subunits, each containing six transmembrane segments, named S1--S6 \[[@B4-biomolecules-10-00010],[@B5-biomolecules-10-00010]\]. A pore region is formed between the pore helix and S6 domain of each subunit, which contains the selectivity filter through which K^+^ ions flow across the plasma membrane \[[@B6-biomolecules-10-00010],[@B7-biomolecules-10-00010]\]. Currently, the structure of the Kv1.5 protein is still awaiting identification; however, alanine-scanning mutagenesis and homologous modeling studies provide us with some amino acids, including Thr479, Ile502, Val505, Ile508, and Val512, which reside within the deep pore (Thr479-Val481) and lower S6 (Cys500-Val512) regions as putative binding sites for open-channel blockers \[[@B8-biomolecules-10-00010],[@B9-biomolecules-10-00010],[@B10-biomolecules-10-00010],[@B11-biomolecules-10-00010],[@B12-biomolecules-10-00010],[@B13-biomolecules-10-00010]\] ([Figure 1](#biomolecules-10-00010-f001){ref-type="fig"}B). This not only helps us to understand the drug targets more comprehensively, but also saves time with regard to the development of potential clinical candidates in the future. From this perspective, we highlight recent advances in the discovery of small molecules as modulators of Kv1.5, and we discuss the structure-activity relationship (SAR) studies of currently used synthetic Kv1.5 inhibitors.

2. Summarization of Models and Mechanisms of Kv1.5 Modulators {#sec2-biomolecules-10-00010}
=============================================================

To date, various kinds of Kv1.5 modulators have been disclosed, herein, we summarize the molecular structures and functionality of different types of Kv1.5 modulators with their chemical structure as follows ([Table 1](#biomolecules-10-00010-t001){ref-type="table"}, [Figure 2](#biomolecules-10-00010-f002){ref-type="fig"}). As shown in [Table 1](#biomolecules-10-00010-t001){ref-type="table"}, the existing Kv1.5 modulators can be divided into four categories: clinical cardiovascular drugs (**1**--**14**), other clinical drugs (**15**--**28**), drugs in development (**29**--**37**), and natural products (**38**--**56**). With the development of pharmacology, more and more experiment models including rats, HEK cells, CHO cells, Xenopus laevis oocytes, and Ltk^-^ cells have been used to evaluate the effect of Kv1.5 channel modulators; the parameters containing mRNA expression, *I*~Kur~, effective refractory period (ERP), and action potential duration (APD) were utilized to reveal the improvement degree of AF. In principle, the Kv1.5 modulators can lengthen the time course of ERP and APD to protect heart from the harm of AF.

Although the structure of Kv1.5 protein has not been characterized yet, current researches provide information for the development of Kv1.5 inhibitors according to fragment-based drug design and structure-based drug design. In regard to the design of Kv1.5 inhibitor, for the instance of the typical candidate vernakalant, in the pharmacophore model, hydrogen bond receptor, hydrogen bond donor, and hydrophobic groups should be present in the structure ([Figure 2](#biomolecules-10-00010-f002){ref-type="fig"}A) to play a role in the transmembrane effect to interact with the Kv1.5 channel. From the potential binding domain of vernakalant in Kv1.5 \[[@B8-biomolecules-10-00010],[@B14-biomolecules-10-00010]\] ([Figure 2](#biomolecules-10-00010-f002){ref-type="fig"}B), we can see that the positively charged moiety bound in the cationophilic inner pore (mainly formed by electron-donating residues including alanine, leucine, and valine) formed a cationic "blocking particle" causing a block of the potassium channel; additionally, the uncharged dimethoxyphenyl moiety of a vernakalant has a tendency to bind in hydrophobic subunit interfaces including residues Ile 502 and Val 505. Functionally important residue isoleucine I502 in the inner helix S6 is exposed into the subunit interface of the pore module rather than into the inner pore. It is worth noting that mutations of Ile 502 decrease the potency of vernakalant, flecainide, and AVE0118, which are the ligands with a long hydrophobic tail in the side chain of the structure.

It seems that the introduction of heterocyclic rings including pyrrole (vernakalant, bepridil, clemizole, and BMS-394136) and piperdine (lobeline, CD-160130, bupivacaine, paroxetine, and donepezil) is important because these moieties usually influence the acidification conditions of the molecules, in which a potentially protonated and thus positively charged drug may enter deeply into the channel pore in a voltage-dependent way \[[@B15-biomolecules-10-00010]\].

As a result of the definite curative effects and pharmacokinetic parameters proved by clinical trials, conventional drugs in new use trends seem to be a feasible way to develop new therapy. Multiple cardiovascular drugs not designed for targeting Kv1.5 have shown Kv1.5 inhibitory effect including quinidine (**9**) and diltiazem (**10**), however, the selectivity of these compounds on Kv1.5 still needs to be investigated.

As for other clinical drugs, CNS agents include: donepezil (**15**), which is generally used as an anti-Alzheimer's agent; paroxetine (**16**), fluoxetine (**17**), and sertraline (**18**), which are usually used as antidepressant agents; and bupivacaine (**23**), propofol (**24**), midazolam (**25**), tolbutamide (**26**), and benzocaine (**27**), which are utilized as anesthetic agents. *h*ERGs (human ether-à-go-go-related genes) are widely associated with CNS diseases \[[@B16-biomolecules-10-00010],[@B17-biomolecules-10-00010],[@B18-biomolecules-10-00010]\], thus it is not strange that active CNS agents can effectively modulate Kv1.5 according to the homology of the protein. Especially the neurotransmitter acetylcholine, which is an important substance that modulates the acetylcholine-activated K^+^ current \[[@B19-biomolecules-10-00010]\], however, only the piperidine type acetylcholine inhibitor donepezil showed significant inhibitory effect on Kv1.5, the same phenomenon was not present in another inhibitor tacrine \[[@B15-biomolecules-10-00010]\], suggesting the selectivity of the binding site of Kv1.5.

Generally, Kv1.5 drugs in development are not going smoothly. The projects listed in [Table 1](#biomolecules-10-00010-t001){ref-type="table"} have been discontinued till now. Effectiveness, toxicity, and druggability should be taken into account at this stage. Persistence of investigation in this field is necessary because the listed compound like AZD-7009 (**30**) can not only alleviate the suffering of patients from intermittent AF but also plays a role in relieving durative AF which continues to attack for more than 48 h \[[@B20-biomolecules-10-00010]\]. The major voltage-gated K^+^ channels expressed in the vasculature are Kv1.2, Kv1.5, Kv2.1, and Kv7.4/7.5 \[[@B21-biomolecules-10-00010]\]. Kv1.3, another Shaker-related family voltage-gated K^+^ channel, is closely related to the *h*ERG channels regulated by Kv1.1 \[[@B22-biomolecules-10-00010]\], which are the important targets influencing the prolongation of Q band to the end of T band (QT) syndrome and torsade pointes attributed to the gain-of-function mutations of clinical candidates whose details are being requested by drug regulatory authorities. Limitations in the ability of high-throughput screening methods to monitor the complex behavior of *h*ERG have restricted the discovery of activators. It is noteworthy that some inhibitors of Kv1.5 channels listed in [Table 1](#biomolecules-10-00010-t001){ref-type="table"} are not specific voltage-gated K^+^ channels for Kv1.5, and some of which also block Kv1.3 channels (e.g., 4-aminopiridine (**2**), nifedipine (**6**), diltiazem (**10**), tetraethylammonium (**11**), propofol (**24**) \[[@B23-biomolecules-10-00010]\], resveratrol (**52**) \[[@B24-biomolecules-10-00010]\], and correolide (**55**)). Application of these drugs may result in side effects related to the inhibition of Kv1.3 channels like immune suppression, thus more attention should be paid to the toxicity to *h*ERG-related targets of Kv1.5 developing candidates. Additionally, in the field of immunization \[[@B25-biomolecules-10-00010]\], nuclear factor erythroid 2-related factor (Nrf2)-induced oxidative stress-inducible protein 1/p62 enhances the inhibition of pulmonary arterial Kv1.5 channels under acute hypoxia, and the 1/p62-Kv1.3-integrin axis provides novel insight into the molecular mechanisms underlying redox-regulated cell signaling in stress-induced biological responses, which broaden future potential directions.

A variety of natural products have been proven to modulate Kv1.5, but the exploration of novel skeleton could be helpful for the current dilemma. Among the isolated compounds, the main types are terpenoids (**38**--**41**), alakaloids (**42**--**47**), and flavonoids (**48**--**50**). Terpenoids are widely reported to inhibit potassium channels \[[@B26-biomolecules-10-00010],[@B27-biomolecules-10-00010],[@B28-biomolecules-10-00010]\], however, the stability and difficulty in preparation because of the lack of a fluorescence group and the abundance in chiral carbon are worth worrying about in the development. Alkaloids, as well as polypeptides like kaliotoxin (**54**) and toxins from marine animals like tetrodotoxin, have been disclosed to inhibit ion channel activity, but the toxicity of these types of compounds is also concerning; after all, *h*ERG toxicity has attracted the attention of the FDA and drugs like bepridil have been withdrawn because of their toxicity \[[@B29-biomolecules-10-00010]\]. Bioactive flavonoids are also proven to modulate the Kv1.5 channel; among them is quercetin (**50**), a minor compound and activator of Kv1.5, with the tendency of developing flavonoids and phenols as health care products or food additives.This class of compounds may play a role in the daily prevention against Kv1.5 disease.

3. Synthetic Kv1.5 Inhibitors and SAR Investigations {#sec3-biomolecules-10-00010}
====================================================

In this section we collated information about chemical synthesis, pharmacological properties, and SAR investigations in the published literature from 2003 to 2019 and summarized them in a timeline. The previous work was briefly introduced in the description ofthe potential synthetic derivatives and chemical structure of compounds, and the SAR studies are listed in the corresponding figures in the perspective of medicinal chemistry. As we can see, multiple scaffolds include 5-methoxypsoralen (**60**,**68**), tetrahydroindolone (**62**--**65**), benzopyran sulfonamides (**70**--**72**), dihydropyrazolopyrimidine (**73**,**81**), and phenylquinazoline (**90**--**92**). Compounds (**86**--**88**) have been reported to be effective in inhibiting Kv1.5, suggesting potential future directions for investigations about Kv1.5 inhibitors. It is noteworthy that research from Bristol-Myers Squibb has contributed greatly with data about pharmacology and pharmacokinetics of active compounds in blocking Kv1.5, increasing the possibility that we can conquer the diseases targeting Kv1.5.

In 2003, Peukert and co-workers \[[@B80-biomolecules-10-00010]\] synthesized a series of ortho-disubstituted bisaryl compounds as blockers of the Kv1.5 channel. Among the derivatives, the most potent compounds **57** (IC~50~: 0.7 μM) and **58** (IC~50~: 0.16 μM) inhibited the Kv1.5 channel with sub-micromolar half-blocking concentrations and displayed three fold selectivity over Kv1.3 and no significant effect on the *h*ERG channel and sodium currents ([Figure 3](#biomolecules-10-00010-f003){ref-type="fig"}).

In 2004, Peukert et al. \[[@B81-biomolecules-10-00010]\] synthesized several anthranilic amides as novel blockers of the Kv1.5 channel. The most hopeful analogue **59** showed moderate Kv1.5 inhibition (IC~50~: 0.7 μM) with good oral bioavailability, however, no significant effect on the *I*~Kr~ current of **59** was detected ([Figure 4](#biomolecules-10-00010-f004){ref-type="fig"}).

Inspired from the precursor 5-methoxypsoralen isolated from *Rutagraveolens*, Schmitz and colleagues \[[@B82-biomolecules-10-00010]\] prepared a series of phenoxyalkoxypsoralen analogues and evaluated their voltage-gated ion channel blocker potency. The most potent and "druglike" compound of this series, 5-(4-phenoxybutoxy) psoralen (PAP-1, **60**), blocks Kv1.3 in a use-dependent manner, with a Hill coefficient of 2 and an EC~50~ of 2 nM, by preferentially binding to the C-type inactivated state of the channel. PAP-1 is 23 fold selective over Kv1.5, 33--125 fold selective over other Kv1 family channels, and 500--7500 fold selective over Kv2.1, Kv3.1, Kv3.2, Kv4.2, *h*ERG, calcium-activated K channels, Na, Ca, and Cl channels. PAP-1 does not exhibit cytotoxic or phototoxic effects, is negative in the Ames test, and affects cytochrome P450-dependent enzymes only at micromolar concentrations ([Figure 5](#biomolecules-10-00010-f005){ref-type="fig"}).

In 2006, Blass et al. \[[@B83-biomolecules-10-00010]\] synthesized a cluster of (2-phenethyl-2*H*-1,2,3-triazol-4-yl) (phenyl) methanone and examined for utility as Kv1.5 channel blockers for the treatment of atrial fibrillation. The results showed that O substitution in the 4-position of the acetophenone-derived portion of the scaffold is highly favored, and the most active compound **61** blockaded Kv1.5 for 99% at a concentration of 1 μM ([Figure 6](#biomolecules-10-00010-f006){ref-type="fig"}).

Fluxe and co-workers \[[@B84-biomolecules-10-00010]\] synthesized multiple tetrahydroindolone-derived carbamates as potent Kv1.5 blockers. The most promising analogues **62** and **63** exhibited the strongest Kv1.5 inhibitory effect with IC~50~ values of 67 and 21 nM, respectively. They were also very selective over *h*ERG (\> 450 fold) and L-type calcium channels (\> 450 fold) ([Figure 7](#biomolecules-10-00010-f007){ref-type="fig"}).

Subsequently, Wu et al. \[[@B85-biomolecules-10-00010]\] designed and synthesized tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers. Compounds **64** and **65** showed good selectivity for the blockade of Kv1.5 (IC~50~: 0.13 μM for two compounds), moreover, in an anesthetized pig model, compounds **64** and **65** increased atrial ERP by about 28% and 18%, respectively, in the right atrium without affecting ventricular ERP ([Figure 8](#biomolecules-10-00010-f008){ref-type="fig"}).

Based on a diisopropyl amide scaffold, a series of potent Kv1.5 ion channel antagonists were synthesized by Nanda and colleagues \[[@B86-biomolecules-10-00010]\]. The most active derivative **66**, which was a single active enantiomer of the diastereomerically pure racemic analog, exhibited significant atrial-selective effects in an in vivo model (IC~50~: 150 nM) ([Figure 9](#biomolecules-10-00010-f009){ref-type="fig"}).

Trotter and co-workers \[[@B87-biomolecules-10-00010]\] designed and synthesized a group of isoquinoline-3-nitriles as orally Kv1.5 antagonists for the treatment of AF. The ethanolamide derivative **67** exhibited improved potency (Kv1.5 HT-Clamp IC~50~: 60 nM), excellent selectivity versus *h*ERG, and good pharmacokinetic properties. Rat EP experiments confirmed that the compound potently increased ARP without significant effects on AVRP^−^ ([Figure 10](#biomolecules-10-00010-f010){ref-type="fig"}).

In 2007, Eun et al. \[[@B88-biomolecules-10-00010]\] synthesized multiple psoralen derivatives as *h*Kvl.5 channel blockers. Among them, compound **68** was the most potent in blocking *h*Kv1.5 (IC~50~: 27.4 nM), much stronger than the lead compound psoralen. Compound **68** accelerated the inactivation kinetics of the *h*Kvl.5 channel and slowed the deactivation kinetics of the *h*Kv1.5 current resulting in a tail crossover phenomenon. Compound **68** inhibited the *h*Kvl.5 current in a use-dependent manner ([Figure 11](#biomolecules-10-00010-f011){ref-type="fig"}).

Jackson and co-workers \[[@B89-biomolecules-10-00010]\] prepared several classes of thiazolidine-based Kv1.5 blockers. The most promising analogue **69** derived from 3,4-dimethylacetophenone exhibited the strongest inhibitory effect with an IC~50~ value of 69 nM ([Figure 12](#biomolecules-10-00010-f012){ref-type="fig"}).

Lloyd et al. \[[@B90-biomolecules-10-00010]\] synthesized a series of benzopyran sulfonamides and determined Kv1.5 potassium channel blocking effects. Among the productions, derivative **70** exhibited the most significant activity (IC~50~: 57 nM), and a moderate inhibition (35%) of *h*ERG at a concentration of 10 μM ([Figure 13](#biomolecules-10-00010-f013){ref-type="fig"}).

In 2008, benzopyran sulfonamides derivatives were further investigated \[[@B91-biomolecules-10-00010]\]. Compound **71** and **72** were considered as the most active derivatives in the two series of compounds with IC~50~ values of 46 and 378 nM in the inhibition of current in a L-929 cell model, respectively. Additionally, at the concentration of 1.0 μM, compound **72** displayed the most significant inbitory effect in the current of L-929 cells with an inhibitory ratio of 89% ([Figure 14](#biomolecules-10-00010-f014){ref-type="fig"}).

Vaccaro and co-workers \[[@B90-biomolecules-10-00010]\] synthesized a series of dihydropyrazolopyrimidine analogues as Kv1.5 inhibitors. The most promising compound **73** showed the best potential in suppressing Kv1.5, with inhibitory effects on *h*ERG (69%) and *I*~Na~^10^ (42%) at a concentration of 10 μM ([Figure 15](#biomolecules-10-00010-f015){ref-type="fig"}).

In 2008, Gross and co-workers \[[@B92-biomolecules-10-00010]\] synthesized aryl sulfonamido tetralin as a Kv1.5 inhibitor according to the basis of previous work. Among the productions, compound **74** exhibited remarkable Kv1.5 inhibitions with an IC~50~ value of 90 nM; in addition, moderate *h*ERG inhibition was detected at the dose of 10 μM (39%), indicating the potential for further development of clinical candidates ([Figure 16](#biomolecules-10-00010-f016){ref-type="fig"}).

According to the structure of marketed drugs amiodarone and vernakalant, Blass et al. \[[@B93-biomolecules-10-00010]\] synthesized a series of imidazolidinone derivatives as a potential treatment for atrial arrhythmia. KVI-020/WYE-160020 (**75**) exhibited the efficacy in clinically relevant models of AF and mechanistic models of the cardiac action potential with acceptable pharmacokinetic and pharmaceutical properties. The pharmacology IC~50~ values for compound **75** in Kv1.5, *h*ERG, Nav1.5, Cav1.3, Cav1.2, Kv1.1, Kv1.3, and Kv4.3 were 0.48, 15.1, \>30, 23.4, \>30, 2.66, 1.41, and 3.87 μM in vitro, respectively ([Figure 17](#biomolecules-10-00010-f017){ref-type="fig"}).

In 2010, Lloyd and co-workers \[[@B58-biomolecules-10-00010]\] developed a series of pyrazolodihydropyrimidines as potent and selective Kv1.5 blockers based on previous studies. The most promising analogue BMS-394136 (**76**) displayed excellent activity in blocking Kv1.5 (IC~50~: 50 nM) and very good selectivity over *h*ERG, sodium, and L-type calcium ion channels with good pharmacokinetic parameters ([Figure 18](#biomolecules-10-00010-f018){ref-type="fig"}).

In 2012, Blass \[[@B94-biomolecules-10-00010]\] prepared several heteroarylsulfonamides as Kv1.5 inhibitors. The active analogues **77**, **78** and **79** exhibited 100% inhibition of Kv1.5 using stably transfected HEK293 cells and the FLIPR potassium ion channel assay, suggesting good potential for further investigation ([Figure 19](#biomolecules-10-00010-f019){ref-type="fig"}).

Finlay and colleagues \[[@B95-biomolecules-10-00010]\] prepared several dihydropyrazolo\[1,5-a\]pyrimidine derivatives. Among the synthetic compounds, compound **80** showed potential to be a selective *I*~Kur~ inhibitor with Kv1.5 IC~50~ of 0.15 μM and *h*ERG with an IC~50~ value \>10 μM. Furthermore, favorable pharmacokinetic properties in rats and dogs of **80** were determined; compound **80** was identified with less than 1% GSH adducts formation with an improved PK profile and equivalent PD efficacy to the lead compound ([Figure 20](#biomolecules-10-00010-f020){ref-type="fig"}).

In 2013, triazolo and imidazo were introduced into the active scaffold dihydropyrazolopyrimidine \[[@B96-biomolecules-10-00010]\]. Trifluoromethylcyclohexyl triazole analogue **81** was identified as a potent and selective Kv1.5 inhibitor (IC~50~: 133 nM) with an acceptable PK and liability profile. Compound **81** demonstrated an improved rat PK profile and was advanced to the rat PD model ([Figure 21](#biomolecules-10-00010-f021){ref-type="fig"}).

With the help of a pharmacophore model, Guo et al. \[[@B97-biomolecules-10-00010]\] designed and synthesized a series of indole derivatives as potent Kv1.5 inhibitors. The most promising compound **82** displayed significant *I*~Na~, HEK 293 *h*Kv1.5, and CHO *h*ERG inhibitory activities with IC~50~ values of 52.6, 0.51, and 418.35 μM, respectively, which displayed remarkable selectivity and ameliorating effects on atrial effective refractory period (AERP) and VERP ([Figure 22](#biomolecules-10-00010-f022){ref-type="fig"}).

Olsson and co-workers \[[@B98-biomolecules-10-00010]\] possessed design and pharmacological evaluation of multiple potential hits targeting on Kv1.5. The compound **83** performed the best in vitro activity with Kv1.5 IC~50~ of 0.08 μM in diphenylphosphinic amide and diphenylphosphine oxide analogues ([Figure 23](#biomolecules-10-00010-f023){ref-type="fig"}). However, both *h*ERG and IKs active and remarkable safety in rats of compound **83** was detected and judged unsuitable for in vivo testing; conversely, the derivative **84** was regarded as a hopeful compound for further development with Kv1.5 IC~50~, IKs, C~eu20~, and QT~max~ change values for 1.0 μM, \>33%, 0.6 μM, and \<10%, respectively.

In 2014, the subsequent study was updated \[[@B99-biomolecules-10-00010]\], and a series of lactam sulfonamide derivatives was prepared and the Kv1.5 inhibitory potency was evaluated. The most promising candidate **85** inhibited Kv1.5 with an IC~50~ value of 0.21 μM and caused a marked increase in the atrium ERP with a C~eu20~ of 0.35 μM, which was at the same order of magnitude as the IC~50~ value from the human cellular assay. The human *h*ERG channel was blocked by compound **85** with an IC~50~ value of 30 μM, indicating a 140 fold margin of the *h*ERG and Kv1.5 in vitro values. No measurable change was noted in the QT-interval in the rabbit experiments, which also indicated a good margin to block of the *h*ERG channel. The compound **85** was well tolerated in rabbits with no signs of the CNS-like side effects observed for other Kv1.5 blockers ([Figure 24](#biomolecules-10-00010-f024){ref-type="fig"}).

Johnson et al. \[[@B100-biomolecules-10-00010]\] synthesized phenethylaminoheterocycles and assayed for inhibition of the Kv1.5 potassium ion channel as a potential approach to the treatment of atrial fibrillation. Combination of the indazole with a cyclohexane-based template gave the most promising derivative **86** (Kv1.5 IC~50~: 138 nM) which demonstrated significant prolongation of AERP in the rabbit pharmacodynamic model ([Figure 25](#biomolecules-10-00010-f025){ref-type="fig"}).

Guo and colleagues \[[@B101-biomolecules-10-00010]\] prepared a series of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors. The most potent compound **87** exerted significant activity on *h*Kv1.5 (IC~50~: 0.72 μM), balanced Log D, and permeability. In addition, comparable in vivo potency with sotalol and dronedarone and remarkable safety in rats of compound **87** were detected as well ([Figure 26](#biomolecules-10-00010-f026){ref-type="fig"}).

In 2016, Kajanus et al. \[[@B102-biomolecules-10-00010]\] synthesized multiple isoindolinone compounds as Kv1.5 blockers. The most potent compounds **88** and **89** exhibited an inhibitory effect with the IC~50~ values of 0.4 and 0.7 µM on Kv1.5, respectively. The above-mentioned two compounds were found to have desirable in vivo PK properties in a mouse model ([Figure 27](#biomolecules-10-00010-f027){ref-type="fig"}).

Finlay and co-workers \[[@B103-biomolecules-10-00010]\] explored phenylquinazoline derivatives as Kv1.5 inhibitors. 5-Phenyl-*N*-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine (**90**) was identified as a potent and ion channel selective inhibitor (Kv1.5 IC~50~: 90 nM, *h*ERG inhibition: 43% at 10 μM) with robust efficacy in the pre-clinical rat ventricular effective refractory period (VERP) model and the rabbit atrial effective refractory period (AERP) model ([Figure 28](#biomolecules-10-00010-f028){ref-type="fig"}).

Subsequently in 2017, Gunaga et al. \[[@B58-biomolecules-10-00010]\] modified the structure of **91** with a series of analogues and evaluated the *I*~Kur~ inhibitory effect. 5-\[5-Phenyl-4-(pyridin-2-ylmethylamino)-quinazolin-2-yl\] pyridine-3-sulfonamide (**92**) was identified as the lead compound in this series with good selectivity over *h*ERG (Kv1.5 IC~50~: 50 nM, *h*ERG IC~50~: 1.9 μM). Compound **91** exhibited robust effects in rabbit and canine pharmacodynamic models and an acceptable cross-species pharmacokinetic profile which was then advanced as a clinical candidate. Further optimization of **91** to mitigate pH-dependent absorption resulted in identification of the corresponding phosphoramide prodrug (**92**) with an improved solubility and pharmacokinetic profile ([Figure 29](#biomolecules-10-00010-f029){ref-type="fig"}).

According to the skeleton of *Agelas* alkaloids clathrodin, oroidin, and hymenidin, Zidar and colleagues \[[@B104-biomolecules-10-00010]\] synthesized multiple derivatives as inhibitors of the voltage-gated potassium channels. The most potent inhibitor was (*E*)-*N*-(3-(2-amino-1H-imidazol-4-yl)allyl)-4,5-dichloro-1H-pyrrole-2-carboxamide (**93**) with IC~50~ values between 1.4 and 6.1 mM against Kv1.3, Kv1.4, Kv1.5, and Kv1.6 channels (Kv1.5 IC~50~: 6.1 μM) ([Figure 30](#biomolecules-10-00010-f030){ref-type="fig"}).

Wolkenberg et al. \[[@B105-biomolecules-10-00010]\] told the story of the development of prospective candidate MK-1832 (**94**) ([Figure 31](#biomolecules-10-00010-f031){ref-type="fig"}). Based on the structure of MK-0448, a cluster of derivatives were synthesized and tested the Kv1.5 inhibitory effect and in vivo and in vitro toxicity. MK-1832 (**94**) was considered to be the best derivative with pharmacological parameters including Kv1.5, I~kur~, and I~kr~(*h*ERG) IC~50~ values for 29, 11 and 1.28 × 10 ^5^ nM, respectively, and pharmacokinetic parameters including dog in vivo atrial refractory period EC~10~ for 14 nM and threshold change in ventricular refractory period \>25 μM.

In 2019, Kajanus and colleagues \[[@B106-biomolecules-10-00010]\] prepared potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents. The most promising analogue **95** displayed significant nanomolar potency in blocking Kv1.5 in human atrial myocytes (IC~50~: 1.7 μM, *I*~Kur~ IC~50~: 60 nM) and based on the PD data, the estimated dose for men was 700 mg/day ([Figure 32](#biomolecules-10-00010-f032){ref-type="fig"}).

Recently, natural products with novel structural motif as a Kv1.5 inhibitor also gained progress in this field. In the sequence of the isolation of compound debromoaplysiatoxin A (**38**) and debromoaplysiatoxin B (**39**) \[[@B63-biomolecules-10-00010]\], Tang and co-workers \[[@B14-biomolecules-10-00010]\] identified other novel aplysiatoxin derivatives from the marine cyanobacterium *Lyngbya* sp. Among them, compound oscillatoxin E (**96**) with the hexane-tetrahydropyran of a spirobicyclic system skeleton exhibited the strongest Kv1.5 inhibition (IC~50~: 0.79 μM) in the CHO cells at an HP of -80 mV ([Figure 33](#biomolecules-10-00010-f033){ref-type="fig"}).

4. Conclusions {#sec4-biomolecules-10-00010}
==============

Herein the target and the pharmacological properties with structural, pharmacological, and SAR information of Kv1.5 modulators were discussed. Detailed descriptions of pharmacology parameters and SAR studies provide an actionable path forward for medicinal chemists to optimize the structure of Kv1.5 modulators. Further experiments should improve the PK and safety after the effectiveness is proven. Design and development of potential and selective Kv1.5 modulators are important and challenging tasks. Based on the existing pharmacophoric requirements and potential protein structure parsed in the future, some novel effective Kv1.5 modulators may be designed and prepared \[[@B107-biomolecules-10-00010],[@B108-biomolecules-10-00010]\]. However, gaps exist in the scientific studies on Kv1.5 modulators. Firstly, the selectivity of existing Kv1.5 modulators remains to be investigated, and more specific modulators aiming at the Kv1.5 channel are needed in the future. Secondly, from the point of application, the market of AF is relatively small, and the sales condition of marked anti-AF agents is not satisfactory as a whole, thus more in-depth pharmacological investigation of roles of Kv1.5 are required in the future. Moreover, the definite structure of Kv1.5 protein is still vacant, difficulties and potential fallacy are still consistent in the design of modulators only estimating by the pocket of homologous models.

SAR investigation is crucial for the development of novel promising clinical candidates. It is anticipated that the information compiled in this review article not only updates researchers with the recently reported pharmacology and SAR of Kv1.5 modulators, but also motivates them to design and synthesize promising Kv1.5 modulators with improved medicinal properties.
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biomolecules-10-00010-t001_Table 1

###### 

Active Kv1.5 modulators.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.                                 Name                                  CAS            Status                                    Model                                           Mechanism                                                                                                                                                                                                                                                                                 Ref.
  ----------------------------------- ------------------------------------- -------------- ----------------------------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  **Clinical Cardiovascular Drugs**                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **1**                               ![](biomolecules-10-00010-i001.jpg)   54-96-6        Approved                                  Smooth muscle cells                             Blocking *h*Kv1.5 current with a threshold fur activation near --45 mV.                                                                                                                                                                                                                   \[[@B30-biomolecules-10-00010]\]

  **2**                               ![](biomolecules-10-00010-i002.jpg)   504-24-5       Approved                                  HEK cells                                       Inhibiting *h*Kv1.5 current after long-term treatment, abbreviating the prolongation of action potential duration in chronic atrial fibrillation (AF).                                                                                                                                    \[[@B31-biomolecules-10-00010]\]

  **3**                               ![](biomolecules-10-00010-i003.jpg)   794466-70-9    Approved, investigational                 HEK cells                                       Selective blocking of the Kv1.5 channel by interacting with important residues including Thr 479, Thr 480, Ile 502, Val 505, and Val 508.                                                                                                                                                 \[[@B32-biomolecules-10-00010]\]

  **4**                               ![](biomolecules-10-00010-i004.jpg)   1951-25-3      Approved, investigational                 Papillary muscles or single ventricular cells   Decreasing the amount of mRNA for Kv1.5.                                                                                                                                                                                                                                                  \[[@B33-biomolecules-10-00010]\]

  **5**                               ![](biomolecules-10-00010-i005.jpg)   54143-55-4     Approved, withdrawn                       Xenopus laevis oocytes                          Producing open-channel block of Kv1.5 by sensitively interacting with key residues including Asp 469, Val 481, and Ile 502 in the S6 region of Kv1.5.                                                                                                                                     \[[@B34-biomolecules-10-00010]\]

  **6**                               ![](biomolecules-10-00010-i006.jpg)   21829-25-4     Approved                                  HEK cells                                       Blocking *h*Kv1.5 channels with 6.3 μM of K~d~ was affected by mutations like Arg 487 similar to those known to affect outer pore C-type inactivation.                                                                                                                                    \[[@B35-biomolecules-10-00010]\]

  **7**                               ![](biomolecules-10-00010-i007.jpg)   54063-53-5     Approved                                  Ltk^-^ cells                                    Inhibiting *h*Kv1.5 current with K~d~value of 9.2 μM, showing time-dependent and dose-dependent manners simultaneously.                                                                                                                                                                   \[[@B36-biomolecules-10-00010]\]

  **8**                               ![](biomolecules-10-00010-i008.jpg)   86384-10-3     \-                                        Ltk^-^ cells                                    Inhibiting *h*Kv1.5 current with K~d~value of 4.4 μM, showing time-dependent and dose-dependent manners simultaneously.                                                                                                                                                                   \[[@B36-biomolecules-10-00010]\]

  **9**                               ![](biomolecules-10-00010-i009.jpg)   56-54-2        Approved, investigational                 HEK cells                                       Producing a voltage-dependent block between +30 and +120 mV (K~d~ at +60 mV = 7.2 μM) with an equivalent electrical distance in the steady state.                                                                                                                                         \[[@B37-biomolecules-10-00010]\]

  **10**                              ![](biomolecules-10-00010-i010.jpg)   42399-41-7     Approved, investigational                 CHO cells                                       Blocking *h*Kv1.5 channels, in a frequency-dependent manner exhibiting a biphasic dose-response curve (IC~50~: 4.8 nM and 42.3 μM) by binding to the open and inactivated state of the channels.                                                                                          \[[@B38-biomolecules-10-00010]\]

  **11**                              ![](biomolecules-10-00010-i011.jpg)   66-40-0        Experimental, investigational             BT-474 breast cancer cell                       Blocking *h*Kv1.5 channels in a delayed rectifier manner.                                                                                                                                                                                                                                 \[[@B39-biomolecules-10-00010]\]

  **12**                              ![](biomolecules-10-00010-i012.jpg)   68379-03-3     \-                                        CHO cells                                       Inhibiting *h*Kv1.5 current with concentration-dependent acceleration of the apparent channel inactivation in both outside-out and inside-out patches.                                                                                                                                    \[[@B40-biomolecules-10-00010]\]

  **13**                              ![](biomolecules-10-00010-i013.jpg)   163163-23-3    \-                                        CHO cells                                       Blocking *h*Kv1.5 current stereoselectivity, the results showed that (-)-\[*3R, 4S*\] was more potent than the (-)-enantiomer.                                                                                                                                                            \[[@B41-biomolecules-10-00010]\]

  **14**                              ![](biomolecules-10-00010-i014.jpg)   64706-54-3     Approved, withdrawn                       HEK cells                                       Inhibiting the *h*Kv1.5 channel current with IC~50~ value of 6.6 μM.                                                                                                                                                                                                                      \[[@B42-biomolecules-10-00010]\]

  **Other Clinical Drugs**                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  **15**                              ![](biomolecules-10-00010-i015.jpg)   120014-06-4    Approved                                  HEK cells                                       Resulting in a rapid and reversible block of Kv1.5 currents (IC~50~: 72.5 μM) with a significant delay in the duration of activation and deactivation, and the outer mouth region proved to be the target site.                                                                           \[[@B15-biomolecules-10-00010]\]

  **16**                              ![](biomolecules-10-00010-i016.jpg)   61869-08-7     Approved, investigational                 CHO cells                                       Slowing the deactivation time course, resulting in a tail crossover phenomenon when the tail currents, recorded in the presence and absence of paroxetine, were superimposed.                                                                                                             \[[@B43-biomolecules-10-00010]\]

  **17**                              ![](biomolecules-10-00010-i017.jpg)   54910-89-3     Approved, vet approved                    Human Pulmonary Artery Smooth Muscle Cells      Protecting against big endothelin-1 induced anti-apoptosis and rescued Kv1.5 channels in human pulmonary arterial smooth muscle cells.                                                                                                                                                    \[[@B44-biomolecules-10-00010]\]

  **18**                              ![](biomolecules-10-00010-i018.jpg)   79617-96-2     Approved                                  CHO cells                                       Reducing Kv1.5 whole-cell currents in a reversible dose-dependent manner and accelerating the decay rate of inactivation of Kv1.5 currents without modifying the kinetics of current activation.                                                                                          \[[@B45-biomolecules-10-00010]\]

  **19**                              ![](biomolecules-10-00010-i019.jpg)   53-06-5        Approved                                  Xenopus oocytes                                 Suppressing the amplitude of Kv1.5 channel current with IC~50~ value of 50.2 μM.                                                                                                                                                                                                          \[[@B46-biomolecules-10-00010]\]

  **20**                              ![](biomolecules-10-00010-i020.jpg)   50-23-7        Approved, vet approved                    Xenopus oocytes                                 Suppressing the amplitude of Kv1.5 channel current with IC~50~ value of 33.4 μM.                                                                                                                                                                                                          \[[@B46-biomolecules-10-00010]\]

  **21**                              ![](biomolecules-10-00010-i021.jpg)   52-01-7        Approved                                  Male Wistar rats                                Shorting the APD~90~(action potential duration) and increasing the expression of Kv1.5.                                                                                                                                                                                                   \[[@B47-biomolecules-10-00010]\]

  **22**                              ![](biomolecules-10-00010-i022.jpg)   169590-42-5    Approved, investigational                 Ltk^-^ cells                                    Blocking *h*Kv1.5 channels with an IC~50~ of 26.2 μM for the peak current and 5.5 μM for the current at the end of a 250 ms pulse to +60 mV.                                                                                                                                              \[[@B48-biomolecules-10-00010]\]

  **23**                              ![](biomolecules-10-00010-i023.jpg)   38396-39-3     Approved, investigational                 Ltk^-^ cells                                    Blocking the opening of *h*Kv1.5 channels stereoselectivity; the results showed the K~d~ value for *R*(+)-enantiomer (4.1 μM) was six-fold more potent than the *S*(-)-enantiomer (27.3 μM).                                                                                              \[[@B49-biomolecules-10-00010],[@B50-biomolecules-10-00010]\]

  **24**                              ![](biomolecules-10-00010-i024.jpg)   2078-54-8      Approved, investigational, vet approved   CHO cells                                       Inducing a time-dependent decline of the *h*Kv1.5 current (IC~50~: 62.9 μM) during depolarizing steps and slowing the time course of tail current decay upon repolarization.                                                                                                              \[[@B4-biomolecules-10-00010]\]

  **25**                              ![](biomolecules-10-00010-i025.jpg)   59467-70-8     Approved                                  HEK cells                                       Inhibited Kv1.5 current (IC~50~: 17 μM) without influence on the half-maximal activation voltage of Kv1.5 channels.                                                                                                                                                                       \[[@B51-biomolecules-10-00010]\]

  **26**                              ![](biomolecules-10-00010-i026.jpg)   64-77-7        Approved, investigational                 Insulin-secreting (INS-1) cells                 Activating Kv1.5 channel and the activation of secretion can be counteracted by an excessive stimulation of Kv channels in INS-1 cells which shorten the Ca^2+^ signal and confine the insulin secretion.                                                                                 \[[@B52-biomolecules-10-00010]\]

  **27**                              ![](biomolecules-10-00010-i027.jpg)   94-09-7        Approved                                  Ltk^-^ cells                                    Blocking *h*Kv1.5 channels in a voltage-dependent manner and modifying the voltage-dependence of channel activation.                                                                                                                                                                      \[[@B53-biomolecules-10-00010]\]

  **Drugs in Development**                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  **28**                              ![](biomolecules-10-00010-i028.jpg)   1163-36-6      Phase 2 Clinical                          HEK cells                                       Decreasing *I*~Ks~ and human Kv1.5 channel current at doses of 3 and 10 μM at voltages ranging from --14.3 to +34.7 mV.                                                                                                                                                                   \[[@B54-biomolecules-10-00010]\]

  **29**                              ![](biomolecules-10-00010-i029.jpg)   767334-89-4    Phase 1 discontinued                      CHO cells                                       Inhibiting *h*Kv1.5 current with IC~50~ value of 3.6 μM, blocking early atrial K^+^ channels, and prolonging atrial refractoriness with no effects on electrocardiography intervals and ventricular repolarization.                                                                       \[[@B55-biomolecules-10-00010]\]

  **30**                              ![](biomolecules-10-00010-i030.jpg)   864368-79-6    Phase 2 discontinued                      CHO cells                                       Blocking *h*Kv1.5 current with IC~50~ value of 27 μM with a slight decrease at higher frequency.                                                                                                                                                                                          \[[@B56-biomolecules-10-00010]\]

  **31**                              ![](biomolecules-10-00010-i031.jpg)   343246-73-1    Phase 1 discontinued                      Mouse fibroblast L929 cells                     Showing excellent activity in blocking Kv1.5 (IC~50~: 0.05 μM) and very good selectivity over *h*ERG, sodium, and L-type calcium ion channels.                                                                                                                                            \[[@B57-biomolecules-10-00010]\]

  **32**                              ![](biomolecules-10-00010-i032.jpg)   1272353-82-8   Phase 1 discontinued                      Mammalian L-929 cells                           Blocking *h*Kv1.5 current with IC~50~ value of 0.05 μM with an acceptable in vitroselectivity and liability profile and a good pharmacokinetic profile across species.                                                                                                                    \[[@B58-biomolecules-10-00010]\]

  **33**                              ![](biomolecules-10-00010-i033.jpg)   875562-81-5    Phase 1 discontinued                      HK2BN9 cells                                    Blocking Kv1.5 current in an expression system and concentration-dependently elevated the plateau phase of atrial action potentials (APs).                                                                                                                                                \[[@B59-biomolecules-10-00010]\]

  **34**                              XEN-D0103\                            1410180-16-3   Phase 2 discontinued                      CHO cells                                       Prolongating action potential duration (APD) and suppressed APs at high stimulation rates in sinus rhythm (SR) and paroxysmal AF (*p*AF) tissue.                                                                                                                                          \[[@B60-biomolecules-10-00010]\]
                                      (Undisclosed structure)                                                                                                                                                                                                                                                                                                                                                                                                                  

  **35**                              ![](biomolecules-10-00010-i034.jpg)   154447-36-6    Experimental                              CHO cells                                       Acting directly on *h*Kv1.5 currents as an open channel blocker with key interacting residues located in the pore region (Thr 480, Arg 487) and the S6 segment (Ile 502, Ile 508, Leu 510, Val 516).                                                                                      \[[@B9-biomolecules-10-00010]\]

  **36**                              ![](biomolecules-10-00010-i035.jpg)   752253-75-1    \-                                        CHO cells                                       Inhibiting several potassium currents including *I*~Kr~, *I*~Ks~, *I*~K(ACh)~, and *I*~Kv1.5~ at doses of 0.01--30 μM.                                                                                                                                                                    \[[@B61-biomolecules-10-00010]\]

  **37**                              ![](biomolecules-10-00010-i036.jpg)   1034194-07-4   \-                                        HEK cells                                       Inhibiting *h*Kv1.5 current slightly when specially blocked by the Kv11.1 channel.                                                                                                                                                                                                        \[[@B62-biomolecules-10-00010]\]

  ***Natural Products***              **Type**                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **38**                              ![](biomolecules-10-00010-i037.jpg)   2334247-91-3   Terpenoid                                 CHO cells                                       Blocking Kv1.5 with an IC~50~ value of 6.94 μM.                                                                                                                                                                                                                                           \[[@B63-biomolecules-10-00010]\]

  **39**                              ![](biomolecules-10-00010-i038.jpg)   2334247-94-6   Terpenoid                                 CHO cells                                       Blocking Kv1.5 with an IC~50~ value of 0.30 μM.                                                                                                                                                                                                                                           \[[@B63-biomolecules-10-00010]\]

  **40**                              ![](biomolecules-10-00010-i039.jpg)   57444-62-9     Terpenoid                                 C6 glioma cells                                 Inhibiting the *h*Kv1.5 current in time and dose-dependent manners.                                                                                                                                                                                                                       \[[@B64-biomolecules-10-00010]\]

  **41**                              ![](biomolecules-10-00010-i040.jpg)   13018-10-5     Terpenoid                                 Ltk^-^ cells                                    Inhibiting the *h*Kv1.5 current in time- and voltage-dependent manners, with an IC~50~ value of 2.51 μM at +60 mV accelerated the inactivation kinetics of the *h*Kv1.5 channel and slowed the deactivation kinetics of the *h*Kv1.5 current, resulting in a tail crossover phenomenon.   \[[@B65-biomolecules-10-00010]\]

  **42**                              ![](biomolecules-10-00010-i041.jpg)   1394-48-5      Alkaloid                                  Guinea pigs                                     Blocking *I*-Kv1.5 slightly with a ratio of 20.6% at a dosage of 200 μM.                                                                                                                                                                                                                  \[[@B66-biomolecules-10-00010]\]

  **43**                              ![](biomolecules-10-00010-i042.jpg)   90-69-7        Alkaloid                                  HEK cells                                       Accelerating the decay rate of Kv1.5 inactivation, decreased the current amplitude at the end of the pulse in a concentration-dependent manner with an IC~50~ value of 15.1 μM.                                                                                                           \[[@B67-biomolecules-10-00010]\]

  **44**                              ![](biomolecules-10-00010-i043.jpg)   4360-12-7      Alkaloid                                  *Xenopus oocytes*                               Inhibiting Kv1.5 with an IC~50~ of 1.70 μM in Xenopus expression system, resulting in a mild leftward shift of Kv1.5 activation curve.                                                                                                                                                    \[[@B68-biomolecules-10-00010]\]

  **45**                              ![](biomolecules-10-00010-i044.jpg)   58-74-2        Alkaloid                                  Ltk^-^ cells                                    Blocking *h*Kv1.5 channels and native *h*Kv1.5 channels in a concentration-, voltage-, state-, and time-dependent manner.                                                                                                                                                                 \[[@B69-biomolecules-10-00010]\]

  **46**                              ![](biomolecules-10-00010-i045.jpg)   2934-97-6      Alkaloid                                  HEK cells                                       Blocking Kv1.5 currents dose-dependently with an IC~50~ value of 53.2 μM inhibited the delayed rectifier effect of Kv1.5 resulting in a potential left shift of the inactivation curve.                                                                                                   \[[@B70-biomolecules-10-00010]\]

  **47**                              ![](biomolecules-10-00010-i046.jpg)   302-27-2       Alkaloid                                  *Xenopus laevis oocytes*                        Producing a voltage-, time-, and frequency-dependent inhibition of Kv1.5 (IC~50~: 0.796 μM).                                                                                                                                                                                              \[[@B71-biomolecules-10-00010]\]

  **48**                              ![](biomolecules-10-00010-i047.jpg)   529-44-2       Flavonoid                                 HEK cells                                       Inhibiting *I*~kur~ and the expression of *h*Kv1.5 in a dose-, time-, and frequency-dependent manner.                                                                                                                                                                                     \[[@B72-biomolecules-10-00010]\]

  **49**                              ![](biomolecules-10-00010-i048.jpg)   5631-70-9      Flavonoid                                 HEK cells                                       Suppressing *h*Kv1.5 current in HEK 293 cell line (IC~50~: 6.4 μM) and the ultra-rapid delayed rectify K^+^ current *I*~Kur~ in human atrial myocytes (IC~50~: 8.0 μM) by binding to open channels in a use- and frequency-dependent manner.                                              \[[@B73-biomolecules-10-00010]\]

  **50**                              ![](biomolecules-10-00010-i049.jpg)   117-39-5       Flavonoid                                 *Xenopus laevisoocytes*                         Activating *h*Kv1.5 channels (EC~50~: 37.8 μM) by interacting with key residue Ile 502 in S6 region.                                                                                                                                                                                      \[[@B74-biomolecules-10-00010]\]

  **51**                              ![](biomolecules-10-00010-i050.jpg)   480-44-4       Flavonoid                                 HEK cells                                       Blocking open *h*Kv1.5 channels by binding to their S6 domain influenced by the interaction of V505A, I508A, and V512A.                                                                                                                                                                   \[[@B75-biomolecules-10-00010]\]

  **52**                              ![](biomolecules-10-00010-i051.jpg)   501-36-0       Phenol                                    Human PASMCs                                    Reducing the expression of Kv1.5 mRNA to reverse monocrotaline-induced pulmonary vascular and cardiac dysfunction.                                                                                                                                                                        \[[@B76-biomolecules-10-00010]\]

  **53**                              ![](biomolecules-10-00010-i052.jpg)   5928-25-6      Coumarin                                  Ltk^−^ cells                                    Inhibiting *h*Kv1.5 current in a concentration- and use-dependent manner, with an IC~50~ value of 2.7 μM at +60 mV accelerated the inactivation kinetics of the *h*Kv1.5 channel, resulting in a tail crossover phenomenon.                                                               \[[@B77-biomolecules-10-00010]\]

  **54**                              Kaliotoxin                            145199-73-1    Polypeptide                               T cell                                          Inhibiting *h*Kv1.5 current in a dose-dependent manner.                                                                                                                                                                                                                                   \[[@B64-biomolecules-10-00010]\]

  **55**                              ![](biomolecules-10-00010-i053.jpg)   190017-00-6    Nor-triterpenoid                          CHO cells                                       Inhibiting Kv1.5 with an IC~50~ of 1.77 μM and influenced by the mutations T480A, V505A, I508A, as well as V516A.                                                                                                                                                                         \[[@B78-biomolecules-10-00010]\]

  **56**                              ![](biomolecules-10-00010-i054.jpg)   107-35-7       Amino acid                                Male Wistar rats                                Down-regulating the mRNA expression level of Kv1.5.                                                                                                                                                                                                                                       \[[@B79-biomolecules-10-00010]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
